About the Product

Description


D-Mannose 600mg + Cranberry Extract 300mg tablet is a urinary tract health support formulation designed for the management and prevention of recurrent urinary tract infections (UTIs).

D-Mannose helps prevent bacterial adhesion to the urinary tract lining, while Cranberry Extract rich in proanthocyanidins supports urinary hygiene by reducing bacterial colonization and promoting natural flushing mechanisms.

This chewable tablet is commonly recommended for recurrent UTIs, urinary discomfort, burning urination, and bladder health maintenance, ensuring improved urinary tract protection and comfort.

With preventive benefits, patient-friendly chewable dosage form, and growing acceptance in urology care, this formulation strengthens a urinary health portfolio and supports consistent demand in preventive urinary management.

This formulation is generally well tolerated. Mild gastrointestinal discomfort, bloating, or nausea may occur in some individuals but usually resolves without intervention.

Uriviga Pro Tablet is indicated for the prevention and supportive management of recurrent urinary tract infections (UTIs), urinary discomfort, burning micturition, and maintenance of urinary tract hygiene, as advised by a healthcare professional.

Use under medical supervision, especially in patients with diabetes or kidney-related conditions. Adequate water intake is recommended during therapy for better urinary tract support.

Store in a cool and dry place below 25°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for D-Mannose 600mg + Cranberry Extract + Proanthocyanidins Chewable Tablets in the PCD pharma franchise market?

This urinary tract health (UTI care) nutraceutical has strong demand in the wellness and preventive healthcare segment, making it a useful product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.

Why should medical distributors include this UTI care chewable tablet in their product range?

Medical distributors and wholesalers can benefit from consistent demand in urinary tract infection prevention, urinary health maintenance, burning urination support, and recurrent UTI management support. It is widely used in preventive urology and women’s health supplements.

Does Cafoli Lifecare offer PCD pharma franchise opportunities for this product?

Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for D-Mannose + Cranberry Extract + Proanthocyanidins Chewable Tablets with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.

What benefits do wholesalers get by partnering for this nutraceutical product?

Wholesalers and medical agencies benefit from strong OTC demand, repeat consumer usage, and growing awareness of urinary tract health and preventive supplements when partnering with Cafoli Lifecare.

How can I become a distributor or franchise partner for this chewable tablet?

Medical distributors, stockists, wholesalers, and pharma professionals interested in this UTI care nutraceutical formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.